We hypothesized B cells are involved in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a progressive, restrictive lung disease that is refractory to glucocorticoids and other nonspecific therapies, and almost invariably lethal. Accordingly, we sought to identify clinically associated B cell–related abnormalities in these patients. Phenotypes of circulating B cells were characterized by flow cytometry. Intrapulmonary processes were evaluated by immunohistochemistry. Plasma B lymphocyte stimulating factor (BLyS) was assayed by ELISA. Circulating B cells of IPF subjects were more Ag differentiated, with greater plasmablast proportions (3.1 ± 0.8%) than in normal controls (1.3 ± 0.3%) (p < 0.03), and the extent of this differentiation correlated with IPF patient lung volumes (r = 0.44, p < 0.03). CD20+ B cell aggregates, diffuse parenchymal and perivascular immune complexes, and complement depositions were all prevalent in IPF lungs, but much less prominent or absent in normal lungs. Plasma concentrations of BLyS, an obligate factor for B cell survival and differentiation, were significantly greater (p < 0.0001) in 110 IPF (2.05 ± 0.05 ng/ml) than among 53 normal (1.40 ± 0.04 ng/ml) and 90 chronic obstructive pulmonary disease subjects (1.59 ± 0.05 ng/ml). BLyS levels were uniquely correlated among IPF patients with pulmonary artery pressures (r = 0.58, p < 0.0001). The 25% of IPF subjects with the greatest BLyS values also had diminished 1-y survival (46 ± 11%), compared with those with lesser BLyS concentrations (81 ± 5%) (hazard ratio = 4.0, 95% confidence interval = 1.8–8.7, p = 0.0002). Abnormalities of B cells and BLyS are common in IPF patients, and highly associated with disease manifestations and patient outcomes. These findings have implications regarding IPF pathogenesis and illuminate the potential for novel treatment regimens that specifically target B cells in patients with this lung disease.

Idiopathic pulmonary fibrosis (IPF) is a morbid, fibroproliferative disorder characterized by progressive lung restriction and gas exchange abnormalities (13). The annual incidence of IPF in the United States is ∼40,000, and afflicted patients have a median survival of ∼3 y (13).

Although the pathogenesis of IPF is widely considered to be enigmatic (2), abnormalities of adaptive immunity are common among patients with this disease (Refs. 422). HLA allele frequency perturbations are a typifying feature of immunological disorders, and HLA-DRβ1*15 is overrepresented among IPF subjects (20), as well as being linked to dysregulated autoimmune responses in this population (13). Infiltrates of activated T cells are present in IPF lungs, and the magnitude of these abnormalities is proportionate to disease severity and patient mortality (19, 21, 22). Circulating T cells among IPF patients are also Ag activated, clonally expanded, dysregulated, and have augmented productions of myriad proinflammatory and profibrotic mediators, and many characteristics of these lymphocytes are associated with clinical manifestations (9, 18, 19). One or more Ags in IPF lungs stimulate autologous CD4 T cells (9), including heat shock protein 70, which induces lymphocyte proliferation and IL-4 production (13).

B cell studies in IPF are more limited, but examinations of diseased lungs from these patients have shown the presence of highly abnormal intrapulmonary B cell aggregates (4, 5) and overexpressions of Ig genes (6). Potentially pathogenic immune complexes have been found in the sera, bronchoalveolar lavage, and pulmonary parenchyma of IPF patients (7, 8, 13). Diverse circulating IgG autoantibodies are present in >80% of these subjects (816), and some particular Ig specificities have been linked to disease severity and/or poor prognoses (1013).

We hypothesized that B cell characteristics and/or their associated mediators may be correlated with clinical features of IPF. If so, these findings could have considerable importance. To begin, the course of IPF is unpredictable among afflicted individuals (2, 3). Thus, facile, valid biomarkers could be very useful to identify patients who are destined for poor near-term outcomes, and thus optimize timings of lung transplantations, and/or aid in selection of high-risk subjects for experimental treatments.

Moreover, the absence of a definitive, mechanistic paradigm of IPF pathogenesis has precluded the rational selection of therapies that are directed specifically at the causal biological process(es) (2, 3). Medical treatments used for IPF to date, typically based on glucocorticoids and/or global antifibrotic drugs, are ineffectual, and the disease continues to have a worse prognosis than several common malignancies (2, 3). Like IPF, many B cell–mediated lung diseases are also refractory to nonspecific therapy with glucocorticoids. Conversely, however, these same syndromes often respond to focused anti–B cell agents or other treatments that reduce concentrations of pathogenic Abs (2329). Hence, finding a compelling link between B cells and IPF progression might engender considerations for experimental trials of recently developed agents that more specifically target these lymphocytes and/or their functions, and may provide some clinical benefit for these otherwise ill-fated patients.

Accordingly, we conducted investigations to characterize B cells and examine a critical B cell mediator in IPF patients that could have therapeutic implications.

Peripheral blood specimens were obtained from consecutive IPF patients (9, 13, 19, 20), healthy volunteers, and subjects with cigarette smoking–attributable chronic obstructive pulmonary disease (COPD) and/or emphysema (30, 31), henceforth collectively denoted as COPD. Plasma was obtained from these specimens by centrifugation, aliquoted, and stored at −80°C prior to use in the B lymphocyte stimulating factor (BLyS) assays. Diagnoses of lung disease were established by expert clinicians, who analyzed all information and were blinded to the experimental laboratory tests. All IPF subjects fulfilled consensus diagnostic criteria (9, 19, 20) and had negative conventional autoimmune serological tests (13). COPD was diagnosed by spirometry (30), and emphysema was detected by chest computerized tomography scans (31). Healthy controls were recruited from volunteers among hospital personnel or research registries. Those with tobacco smoking histories had normal spirometry and no radiographic evidence of emphysema.

Subpopulations of IPF and COPD subjects had pulmonary artery (PA) pressures (PAP) measured by right heart catheterizations during evaluations for possible lung transplantation, or other clinical indications. These catheterizations were performed by cardiologists who were independent and unaware of this study.

All subjects gave written informed consent. This study was approved by the University of Pittsburgh Institutional Review Board.

PBMCs were isolated from venous phlebotomy specimens by density gradient centrifugation (9). B cells among the PBMCs were stained with panels of mAb and characterized by flow cytometry, as fully detailed previously (32). B lymphocytes were identified as CD3/CD14/CD16/CD19+ cells, and further stratified for comparisons in this study as transitional (IgD+/CD38++), IgM+ IgA IgG switched memory (IgD+/CD27+), IgG+ switched memory (IgD/CD27+/−), and plasmablasts (CD19low/+, CD20, CD38++, IgD, CD27++) (Fig. 1A).

FIGURE 1.

Phenotypes of circulating B cells. (A) Cells were stained with panels of mAb and gated on CD19+, CD20, CD3, and IgD B cells. Plasmablasts among these (CD2hi, CD38hi ) are denoted in the upper right quadrant of this example. (B) Selected phenotypic characteristics of circulating B cells among COPD (n = 29), IPF (n = 25), and normal controls (n = 20). The lowest, second lowest, middle, second highest, and highest box points represent 10th, 25th, median, 75th, and 90th percentiles, respectively. Means are represented by squares. Trans refers to transitional (recent bone marrow emigrant B cell) and successively differentiated developmental stages: non-isotype switched (IgA, IgG) memory (nsMem), isotype (IgG) switched memory (sMEM), and efficient Ab-producing plasmablasts (PB). Absolute sMEM values are 10× those depicted in this figure. The p values denote Kruskal–Wallis comparisons of the three cohorts: *denotes the group that is significantly different from the other two. Note increased B cell differentiation among the disease cohorts (COPD and IPF) relative to healthy controls, and the general similarities between those two lung disease subpopulations. (C) The percentage of plasmablasts (PB) among circulating B cells was inversely correlated with FVC, as a percentage of predicted values (FVC%p) in IPF subjects. (D) The percentage of plasmablasts (PB) among circulating B cells was inversely correlated with DLCO%p in COPD subjects.

FIGURE 1.

Phenotypes of circulating B cells. (A) Cells were stained with panels of mAb and gated on CD19+, CD20, CD3, and IgD B cells. Plasmablasts among these (CD2hi, CD38hi ) are denoted in the upper right quadrant of this example. (B) Selected phenotypic characteristics of circulating B cells among COPD (n = 29), IPF (n = 25), and normal controls (n = 20). The lowest, second lowest, middle, second highest, and highest box points represent 10th, 25th, median, 75th, and 90th percentiles, respectively. Means are represented by squares. Trans refers to transitional (recent bone marrow emigrant B cell) and successively differentiated developmental stages: non-isotype switched (IgA, IgG) memory (nsMem), isotype (IgG) switched memory (sMEM), and efficient Ab-producing plasmablasts (PB). Absolute sMEM values are 10× those depicted in this figure. The p values denote Kruskal–Wallis comparisons of the three cohorts: *denotes the group that is significantly different from the other two. Note increased B cell differentiation among the disease cohorts (COPD and IPF) relative to healthy controls, and the general similarities between those two lung disease subpopulations. (C) The percentage of plasmablasts (PB) among circulating B cells was inversely correlated with FVC, as a percentage of predicted values (FVC%p) in IPF subjects. (D) The percentage of plasmablasts (PB) among circulating B cells was inversely correlated with DLCO%p in COPD subjects.

Close modal

Pulmonary explant specimen processing has been detailed elsewhere (9, 13). IPF and COPD explants were obtained during therapeutic transplantations. Normal lungs not used for transplantations were procured from cadaveric donors during harvests of other organs (9, 13).

These studies were performed using methods that have been previously detailed (30). Primary Abs used on Zn-fixed lung sections were mouse anti-human IgG (Serotec, Raleigh, NC) and rabbit anti-human C4d (LSBio, Seattle, WA). Treatments with these Abs were followed by successive incubations with species and isotype-specific biotinylated secondary Abs and avidin-HRP (30). Mouse anti-human CD20 (Dako, Carpinteria, CA) and anti–Ki-67 (ThermoFisher, Kalamazoo, MI) were analogously used in formalin-fixed, paraffin-embedded lung specimens. Intrapulmonary B cell aggregates were quantified by blinded observers who counted CD20+ cells in 30 successive, defined rectangular fields in each individual lung tissue specimen (at original magnification ×10). These data are expressed as numbers of CD20+ cells/mm2.

Plasma was obtained by centrifugation of heparinized phlebotomy specimens and used in BLyS ELISA kits (R&D Systems), according to manufacturer instructions. OD at 405 nm for replicate specimens were determined in a SpectraMax 190 plate reader (Molecular Devices, Sunnyvale, CA), blanked against untreated wells.

Two- and three-group comparisons of continuous variables were made by Mann–Whitney or Kruskal-Wallis tests, respectively. Associations between continuous variables were established by linear regression. Logistic regression was used to perform multivariate analyses. Survival analyses were performed using product-limit estimation, with intergroup comparisons by log rank. Hazard ratios and 95% confidence interval were established by proportional hazard regression. The p values <0.05 were considered significant. Unless otherwise denoted, data are depicted as means ± SE.

Plasma specimens for BLyS assays were collected between December 28, 2005 and December 16, 2011. Characteristics of the aggregate lung disease populations used in these studies are detailed in Table I. Normal controls (n = 53) were 63 ± 1 y old, 64% male, and 57% were former or current smokers.

Table I.
Demographic and clinical characteristics of lung disease subjects in whom BLyS was quantified
IPFCOPD
n 110 90 
Age (y) 69 ± 1 (71, 51–87) 64 ± 1 (65, 47–83)a 
Gender (% male) 73 44a 
FVC % predicted 62 ± 2 (59, 25–113) 81 ± 2 (82, 35–136)a 
FEV1 % predicted 75 ± 2 (73, 31–130) 53 ± 3 (54, 12–121)a 
FEV1/FVC 0.85 ± 0.01 (0.85, 0.71–1.22) 0.48 ± 0.02 (0.46, 0.15–0.81)a 
DLCO % predicted 47 ± 2 (47, 14–110) 51 ± 2 (48, 12–122) 
Smoking history (%) 55 100a 
IPFCOPD
n 110 90 
Age (y) 69 ± 1 (71, 51–87) 64 ± 1 (65, 47–83)a 
Gender (% male) 73 44a 
FVC % predicted 62 ± 2 (59, 25–113) 81 ± 2 (82, 35–136)a 
FEV1 % predicted 75 ± 2 (73, 31–130) 53 ± 3 (54, 12–121)a 
FEV1/FVC 0.85 ± 0.01 (0.85, 0.71–1.22) 0.48 ± 0.02 (0.46, 0.15–0.81)a 
DLCO % predicted 47 ± 2 (47, 14–110) 51 ± 2 (48, 12–122) 
Smoking history (%) 55 100a 

Data are depicted as means ± SE, and in parentheses: (median, minimum-to-maximum values). FVC % predicted = FVC, as a percentage of predicted values; FEV1 % predicted = FEV in the first second of expiration, as a percentage of predicted values; FEV1/FVC = the ratio of FEV in the first second to FVC; DLCO % predicted = diffusing capacity for carbon monoxide, as a percentage of predicted values. Smoking history denotes subjects with ≥5 pack years of cigarette smoking.

a

p < 0.0001 for nonparametric comparisons between the COPD and IPF cohorts.

To conduct an initial evaluation for B cell abnormalities in the respective cohorts, the phenotypes of their circulating lymphocytes were prospectively determined by flow cytometry among recently recruited consecutive subjects. Characteristics of the subjects who provided these specimens are detailed in Supplemental Table I.

B cell phenotype distributions among the IPF patients were abnormal compared with healthy subjects, and similar to those of the subjects with COPD (Fig. 1B), a clinically distinct lung disease in which pathogenic autoantibodies have been implicated (30). The magnitude of plasmablast differentiation among the IPF subjects was inversely correlated with forced vital capacities (FVC), a measure of lung restriction (Fig. 1C). There was a trend in the COPD cohort for an analogous inverse correlation between the proportion of plasmablasts among B cells and the ratio of forced expiratory volume (FEV) in the first second of expiration to FVC (FEV1/FVC), a defining criterion of expiratory airflow obstruction (r = 0.32, p = 0.09). Plasmablast differentiation among the COPD subjects was significantly correlated with diffusing capacities for carbon monoxide, a correlate of intrapulmonary gas exchange (Fig. 1D).

Having found evidence of circulating B cell abnormalities in IPF patients, we performed additional studies to confirm these lymphocytes were also present within patient lungs. Focal aggregates of CD20+ B cells were present in all IPF lungs examined by immunohistochemistry (n = 11), typically proximate to small airways, and to a somewhat lesser extent near small blood vessels (Fig. 2A). Fewer and typically more scattered CD20+ cells were evident in normal lungs (n = 9) (Fig. 2B). Ki-67 was only infrequently seen among the IPF B cells (Fig. 2A).

FIGURE 2.

Intrapulmonary CD20+ B cells. (A) Representative images show sections from normal lungs (left panel) and IPF lungs (middle panel) immunostained for CD20. These B cells are only infrequently positive for Ki-67 (right panel) (original magnification ×100). (B) Direct counting confirmed CD20+ cells are more numerous in IPF compared to normal lung specimens.

FIGURE 2.

Intrapulmonary CD20+ B cells. (A) Representative images show sections from normal lungs (left panel) and IPF lungs (middle panel) immunostained for CD20. These B cells are only infrequently positive for Ki-67 (right panel) (original magnification ×100). (B) Direct counting confirmed CD20+ cells are more numerous in IPF compared to normal lung specimens.

Close modal

Analogous B cell aggregates were also evident in COPD lung sections (data not shown), as previously described and illustrated (33).

BLyS plasma concentrations were significantly greater among IPF subjects than in both normal and COPD controls (Fig. 3A). BLyS concentrations were highest among those IPF subjects who had PA hypertension, defined as PA mean pressure >25 mmHg with PA wedge pressure <15 mmHg, and also among those who died within 1 y of the specimen acquisitions (Fig. 3B). The BLyS values were significantly correlated with PAP among individuals with IPF (Fig. 3C). Pulmonary function tests were obtained 6.1 ± 0.3 mo in 64 of the IPF subjects (those still alive, not transplanted, or not too ill to perform these tests). BLyS concentrations in these patients tended to be inversely associated with subsequent changes in FVC (r = 0.26, p = 0.04).

FIGURE 3.

BLyS levels. (A) Plasma BLyS concentrations were significantly greater in IPF subjects (n = 110) than in either COPD (n = 90) or normals (n = 53). (B) Among the IPF cohort, BLyS levels were highest among those who died during the next year (n = 25), and in those who had pulmonary artery hypertension (PAH) (n = 17), compared to those with lesser pulmonary artery (PA) mean pressures (Nl) (n = 28). PAH was defined as PA mean pressures >25 mmHg with PA wedge (PAW) pressures <15 mmHg. Subjects with PAW >15 were not tabulated here (n = 5). These five excluded subjects had PA mean pressures >25, and their BLyS concentrations were 1.92 ± 0.32 ng/ml). (C) BLyS concentrations were correlated with pulmonary artery pressures among IPF subjects. (D) The quartile (25%) of IPF subjects with greatest BLyS levels (High) had worse outcomes than those subjects with lesser BLyS levels (Low). Cross-hatches and numbers in parentheses denote censored events (end of observation). (E) Absolute mortality was also greater among IPF patients with the highest quartile plasma BLyS concentrations (High) after omission of the subpopulation that had lung transplantations during the observation interval.

FIGURE 3.

BLyS levels. (A) Plasma BLyS concentrations were significantly greater in IPF subjects (n = 110) than in either COPD (n = 90) or normals (n = 53). (B) Among the IPF cohort, BLyS levels were highest among those who died during the next year (n = 25), and in those who had pulmonary artery hypertension (PAH) (n = 17), compared to those with lesser pulmonary artery (PA) mean pressures (Nl) (n = 28). PAH was defined as PA mean pressures >25 mmHg with PA wedge (PAW) pressures <15 mmHg. Subjects with PAW >15 were not tabulated here (n = 5). These five excluded subjects had PA mean pressures >25, and their BLyS concentrations were 1.92 ± 0.32 ng/ml). (C) BLyS concentrations were correlated with pulmonary artery pressures among IPF subjects. (D) The quartile (25%) of IPF subjects with greatest BLyS levels (High) had worse outcomes than those subjects with lesser BLyS levels (Low). Cross-hatches and numbers in parentheses denote censored events (end of observation). (E) Absolute mortality was also greater among IPF patients with the highest quartile plasma BLyS concentrations (High) after omission of the subpopulation that had lung transplantations during the observation interval.

Close modal

To examine for possible associations of BLyS with subsequent outcomes, the IPF patients were stratified into the quartile with highest circulating concentrations of this mediator versus the 75% of subjects with lower BLyS levels. Actuarial analyses confirmed that subjects with the greatest concentrations of BLyS had worse 1-y outcomes (Fig. 3D). Post hoc actuarial analyses limited to tabulations of deaths, with omission of those subjects who had transplantations during the year after their specimen acquisitions, also showed greater 1-y absolute survival among the IPF subjects with lower BLyS concentrations (Fig. 3E).

There were no significant gender differences of BLyS levels among the IPF patients (2.1 ± 0.1 versus 1.9 ± 0.1 ng/ml, for males and females, respectively, p = 0.66), but there was a trend for greater proportions of males within the quartile of subjects with highest BLyS concentrations (Table II). Otherwise, there were no appreciable associations of the clinical/demographic parameters in Table II with levels of this mediator. None of these clinical/demographic characteristics were associated with survival independently of BLyS. PAP was also not an independent correlate of outcome in this study cohort.

Table II.
Demographic and clinical characteristics of IPF subjects stratified by plasma BLyS levels
Lowest BLySHighest BLyS
n 82 28 
Age (y) 70 ± 1 (71, 53–87) 67 ± 2 (69, 51–82) 
Gender (% male) 68 86 
Lung biopsy (%) 51 61 
FVC % predicted 63 ± 2 (61, 31–113) 59 ± 4 (57, 25–102) 
DLCO % predicted 49 ± 2 (48, 14–109) 44 ± 4 (40, 14–91) 
Smoking history (%) 59 44 
Immunosuppressants (%) 19 18 
Lowest BLySHighest BLyS
n 82 28 
Age (y) 70 ± 1 (71, 53–87) 67 ± 2 (69, 51–82) 
Gender (% male) 68 86 
Lung biopsy (%) 51 61 
FVC % predicted 63 ± 2 (61, 31–113) 59 ± 4 (57, 25–102) 
DLCO % predicted 49 ± 2 (48, 14–109) 44 ± 4 (40, 14–91) 
Smoking history (%) 59 44 
Immunosuppressants (%) 19 18 

Highest BLyS denotes those IPF subjects with mediator levels in the greatest quartile of values, whereas lowest BlyS denotes the 75% of subjects with lower values. Data are depicted as means ± SE, and in parentheses: (median, minimum-to-maximum values). Immunosuppressants denote subjects taking any single agent or various permutations of prednisone (5–20 mg/day), azathioprine, IFN-γ, mycophenolate, or tacrolimus. See Table I legend for other explanations. None of these characteristics differed significantly between the subpopulations (p = 0.07 for the intergroup gender comparisons).

To date, very few of the COPD cohort have died (precluding meaningful analyses of survival correlates). However, BLyS levels in COPD subjects did not significantly correlate with PAP (r = 0.20, p = 0.21) or measures of pulmonary function (data not shown). There were no differences of circulating BLyS concentrations between males (1.56 ± 0.08 ng/ml) and females (1.62 ± 0.06 ng/ml) among the COPD cohort. Proportions of males and females in the highest quartile of BLyS concentrations among COPD subjects were 25 and 24%, respectively.

Given the association between BLyS and PAP, we examined lung sections for evidence of Ab-mediated processes involving pulmonary blood vessels (Fig. 4). Diffuse parenchymal immune complexes and complement depositions were much more extensive in IPF lungs compared with normals, as has been previously described (13). Also, in contrast to normal lung specimens, the IPF sections were characterized by thickened blood vessel walls and adventitia that are associated with wider circumferential IgG and C4d staining. These findings were particularly conspicuous in areas proximate to extensive fibrotic abnormalities of lung parenchyma. The presences of intrapulmonary immune complexes and complement depositions in COPD have already been detailed (30).

FIGURE 4.

Intrapulmonary IgG and C4d. In contrast to normal lungs, the IPF sections are characterized by more intense IgG and C4d staining throughout the parenchyma, and particularly intense staining around blood vessels (black arrows). Staining was also present in lymphoid aggregates (red arrows) and intraluminal cells and debris (green arrows). Inset images show the lack of staining in nonimmune controls (original magnification ×100).

FIGURE 4.

Intrapulmonary IgG and C4d. In contrast to normal lungs, the IPF sections are characterized by more intense IgG and C4d staining throughout the parenchyma, and particularly intense staining around blood vessels (black arrows). Staining was also present in lymphoid aggregates (red arrows) and intraluminal cells and debris (green arrows). Inset images show the lack of staining in nonimmune controls (original magnification ×100).

Close modal

Ag-stimulated B cells undergo incremental maturations that result in highly differentiated lymphocytes with increased efficacy for the elaboration of avid, isotype-switched IgG Abs (34). In comparisons with healthy controls, B cell phenotypes among patients with recognized autoantibody diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), are more differentiated, with lesser proportions of early B cells and greater relative proportions of mature lymphocytes, including autoantibody-producing plasmablasts (3537). Moreover, the magnitude of this B cell differentiation is a biomarker for the clinical activities of these diseases (3537). The present data show the extent of B lymphocyte differentiation among IPF subjects is similarly abnormal (Fig. 1B) and is also analogously correlated with the pulmonary function of these lung disease patients (Fig. 1C).

Other findings in this study confirm previous reports of abnormal B cell aggregates within IPF lungs (4, 5) (Fig. 2). The B cell accumulations in these specimens are predominately Ki-67 negative, and thus are almost certainly attributable to trafficking from extrapulmonary compartments rather than local proliferation. This particular finding is also congruent with a previous report (5).

BLyS, also known as B cell–activating factor, is a TNF ligand family cytokine that is produced by a variety of leukocytes, and provides essential, nonredundant signals necessary for B lymphocyte survival, maturation, and Ab production (29, 38). Circulating BLyS is increased in patients with many autoantibody-mediated diseases, including SLE and rheumatoid arthritis, and levels of this mediator among individuals with these diseases are associated with their clinical manifestations (29, 38, 39). The present data show that plasma concentrations of BLyS are similarly increased in IPF subjects, as well as also being correlated with important clinical features and prognoses of these patients (Fig. 3). PAP were measured in this study among patient subpopulations that had these determinations during evaluations for lung transplantations and/or other clinical indications (e.g., for disproportionate dyspnea). Accordingly, it is possible the cohorts with these measures were biased, which could have included an enrichment of patients with pulmonary artery hypertension. Thus, the association of BLyS with PAP may not be as rigorous in cross-sectional, unselected IPF populations. Nonetheless, the IPF subpopulation analyzed in this study also included many patients with normal PAP in whom the BLyS-PAP association was still evident (Fig. 3C). Most importantly, circulating BLyS concentrations were also highly associated with patient outcomes (Fig. 3D, 3E), and the latter analyses are not subject to selection bias.

The findings in this study are further evidence that B cell abnormalities are common in IPF subjects (416) and linked to clinical manifestations and mortality (1013). Studies of B cells in IPF are ongoing, but there are several plausible mechanisms by which these lymphocytes could have pathogenic effects.

Tissue-bound Abs produced by B cells can cause cytotoxicities and promote neutrophil recruitment by the formation of Ab-Ag (immune) complexes and complement fixation (Fig. 4), and/or by activation of NK cells (17, 34, 40, 41). Observations in this study confirm previous findings of diffuse immune complex and complement depositions in IPF lungs (13), and additionally show these processes are proximally associated with intrapulmonary blood vessel pathology (Fig. 4).

Autoantibodies can also deleteriously alter target cell functions (13, 16, 42, 43) by cross-linking cell surface autoantigen-receptor complexes that transduce and enhance proinflammatory responses, or after gaining access to intracellular autoantigens (44). Previous studies have shown that autoantibodies of IPF patients increase the production of profibrotic TGF-β by alveolar epithelia (16). Anti–heat shock protein 70 IgG isolated from these patients activates monocytes and increases their elaborations of IL-8 (13), a chemokine biomarker of IPF that has been implicated in the pathogenesis of this disease (45).

Although perhaps less widely appreciated, activated B cells per se also directly elaborate numerous cytokines and other mediators that have vasoactive, proinflammatory, and profibrotic effects (34). Intrapulmonary lymphoid aggregates are an abundant source of diverse, highly active mediators, essentially always an abnormal finding, and most likely have pathogenic consequences (5, 34, 46, 47). Lymphoid aggregates in proximity to pulmonary blood vessels are associated with anatomic and functional vascular abnormalities among IPF and other disease populations (5, 47).

Activated B cells are also efficient APCs for T lymphocytes (34). In turn, Ag (or autoantigen)-stimulated T cells produce myriad pathogenic mediators (48), and have been singularly implicated as the initiators of many disease-associated inflammatory cascades, including those that result in pathological fibrosis (41, 48, 49). Numerous T cell abnormalities have been described in IPF patients, including reactivity to autologous lung proteins and intrapulmonary autoantigens, and several characteristics and functions of these lymphocytes are correlated with clinical manifestations and/or patient outcomes (9, 13, 18, 19, 21, 22).

The present data, in conjunction with other independent evidences in IPF patients (422), illuminate several parallels between this lung disease and recognized autoimmune syndromes (3439, 41, 42, 46, 49). Thus, these collective findings may be an impetus to consider innovative experimental trials for this inexorable and highly lethal syndrome. Severe autoantibody-mediated lung diseases in particular (e.g., Goodpasture’s disease, anti–Jo-1–associated interstitial lung disease, Wegener’s granulomatosis, anti-alloantigen–mediated rejection, etc.) are usually inadequately responsive or even refractory to corticosteroid-based therapy. However, these disorders are often more responsive to treatments with modalities that remove autoantibodies [e.g., plasma exchange (23)] and/or B cell–depleting agents, including rituximab (2427), and a preliminary report indicates this approach may also possibly benefit IPF patients (50). Alternatively, or in addition, critical B cell functions can be targeted by interfering with the maturation and survival of these lymphocytes (29, 38). A highly specific anti-BLyS agent (belimumab) was recently approved by the Food and Drug Administration for treatment of Ab-mediated SLE, and this drug appears to have efficacy and minimal toxicity in this indication (28).

If humoral autoimmunity plays a pathogenic role in IPF causality or progression, as suggested by the current findings and several other reports (417), mechanistic therapies that specifically target B cells could perhaps benefit patients afflicted with this morbid and heretofore untreatable disease (2, 3, 50).

This work was supported in part by National Institutes of Health Grants HL107172 and HL084948.

The online version of this article contains supplemental material.

Abbreviations used in this article:

BLyS

B lymphocyte stimulating factor

COPD

chronic obstructive pulmonary disease

FEV

forced expiratory volume

FVC

forced vital capacity

IPF

idiopathic pulmonary fibrosis

PA

pulmonary artery

PAP

PA pressure

SLE

systemic lupus erythematosus.

1
Fernández Pérez
E. R.
,
Daniels
C. E.
,
Schroeder
D. R.
,
St. Sauver
J.
,
Hartman
T. E.
,
Bartholmai
B. J.
,
Yi
E. S.
,
Ryu
J. H.
.
2010
.
Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.
Chest
137
:
129
137
.
2
Borchers
A. T.
,
Chang
C.
,
Keen
C. L.
,
Gershwin
M. E.
.
2011
.
Idiopathic pulmonary fibrosis: an epidemiological and pathological review.
Clin. Rev. Allergy Immunol.
40
:
117
134
.
3
O’Connell
O. J.
,
Kennedy
M. P.
,
Henry
M. T.
.
2011
.
Idiopathic pulmonary fibrosis: treatment update.
Adv. Ther.
28
:
986
999
.
4
Campbell
D. A.
,
Poulter
L. W.
,
Janossy
G.
,
du Bois
R. M.
.
1985
.
Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity.
Thorax
40
:
405
411
.
5
Marchal-Sommé
J.
,
Uzunhan
Y.
,
Marchand-Adam
S.
,
Valeyre
D.
,
Soumelis
V.
,
Crestani
B.
,
Soler
P.
.
2006
.
Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis.
J. Immunol.
176
:
5735
5739
.
6
Zuo
F.
,
Kaminski
N.
,
Eugui
E.
,
Allard
J.
,
Yakhini
Z.
,
Ben-Dor
A.
,
Lollini
L.
,
Morris
D.
,
Kim
Y.
,
DeLustro
B.
, et al
.
2002
.
Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans.
Proc. Natl. Acad. Sci. USA
99
:
6292
6297
.
7
Dall’Aglio
P. P.
,
Pesci
A.
,
Bertorelli
G.
,
Brianti
E.
,
Scarpa
S.
.
1988
.
Study of immune complexes in bronchoalveolar lavage fluids.
Respiration
54(Suppl. 1)
:
36
41
.
8
Dobashi
N.
,
Fujita
J.
,
Murota
M.
,
Ohtsuki
Y.
,
Yamadori
I.
,
Yoshinouchi
T.
,
Ueda
R.
,
Bandoh
S.
,
Kamei
T.
,
Nishioka
M.
, et al
.
2000
.
Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis.
Lung
178
:
171
179
.
9
Feghali-Bostwick
C. A.
,
Tsai
C. G.
,
Valentine
V. G.
,
Kantrow
S.
,
Stoner
M. W.
,
Pilewski
J. M.
,
Gadgil
A.
,
George
M. P.
,
Gibson
K. F.
,
Choi
A. M.
, et al
.
2007
.
Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis.
J. Immunol.
179
:
2592
2599
.
10
Ogushi
F.
,
Tani
K.
,
Endo
T.
,
Tada
H.
,
Kawano
T.
,
Asano
T.
,
Huang
L.
,
Ohmoto
Y.
,
Muraguchi
M.
,
Moriguchi
H.
,
Sone
S.
.
2001
.
Autoantibodies to IL-1 α in sera from rapidly progressive idiopathic pulmonary fibrosis.
J. Med. Invest.
48
:
181
189
.
11
Kurosu
K.
,
Takiguchi
Y.
,
Okada
O.
,
Yumoto
N.
,
Sakao
S.
,
Tada
Y.
,
Kasahara
Y.
,
Tanabe
N.
,
Tatsumi
K.
,
Weiden
M.
, et al
.
2008
.
Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis.
J. Immunol.
181
:
756
767
.
12
Taillé
C.
,
Grootenboer-Mignot
S.
,
Boursier
C.
,
Michel
L.
,
Debray
M. P.
,
Fagart
J.
,
Barrientos
L.
,
Mailleux
A.
,
Cigna
N.
,
Tubach
F.
, et al
.
2011
.
Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis.
Am. J. Respir. Crit. Care Med.
183
:
759
766
.
13
Kahloon
R. A.
,
Xue
J.
,
Bhargava
A.
,
Csizmadia
E.
,
Otterbein
L.
,
Kass
D. J.
,
Bon
J.
,
Soejima
M.
,
Levesque
M. C.
,
Lindell
K. O.
, et al
.
2013
.
Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.
Am. J. Respir. Crit. Care Med.
187
:
768
775
.
14
Grigolo
B.
,
Mazzetti
I.
,
Borzì
R. M.
,
Hickson
I. D.
,
Fabbri
M.
,
Fasano
L.
,
Meliconi
R.
,
Facchini
A.
.
1998
.
Mapping of topoisomerase II alpha epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis.
Clin. Exp. Immunol.
114
:
339
346
.
15
Yang
Y.
,
Fujita
J.
,
Bandoh
S.
,
Ohtsuki
Y.
,
Yamadori
I.
,
Yoshinouchi
T.
,
Ishida
T.
.
2002
.
Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.
Clin. Exp. Immunol.
128
:
169
174
.
16
Wallace
W. A.
,
Howie
S. E.
.
2001
.
Upregulation of tenascin and TGFbeta production in a type II alveolar epithelial cell line by antibody against a pulmonary auto-antigen.
J. Pathol.
195
:
251
256
.
17
Magro
C. M.
,
Waldman
W. J.
,
Knight
D. A.
,
Allen
J. N.
,
Nadasdy
T.
,
Frambach
G. E.
,
Ross
P.
,
Marsh
C. B.
.
2006
.
Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies.
Hum. Immunol.
67
:
284
297
.
18
Kotsianidis
I.
,
Nakou
E.
,
Bouchliou
I.
,
Tzouvelekis
A.
,
Spanoudakis
E.
,
Steiropoulos
P.
,
Sotiriou
I.
,
Aidinis
V.
,
Margaritis
D.
,
Tsatalas
C.
,
Bouros
D.
.
2009
.
Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis.
Am. J. Respir. Crit. Care Med.
179
:
1121
1130
.
19
Gilani
S. R.
,
Vuga
L. J.
,
Lindell
K. O.
,
Gibson
K. F.
,
Xue
J.
,
Kaminski
N.
,
Valentine
V. G.
,
Lindsay
E. K.
,
George
M. P.
,
Steele
C.
,
Duncan
S. R.
.
2010
.
CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis.
PLoS One
5
:
e8959
.
20
Xue
J.
,
Gochuico
B. R.
,
Alawad
A. S.
,
Feghali-Bostwick
C. A.
,
Noth
I.
,
Nathan
S. D.
,
Rosen
G. D.
,
Rosas
I. O.
,
Dacic
S.
,
Ocak
I.
, et al
.
2011
.
The HLA class II allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis.
PLoS One
6
:
e14715
.
21
Parra
E. R.
,
Kairalla
R. A.
,
Ribeiro de Carvalho
C. R.
,
Eher
E.
,
Capelozzi
V. L.
.
2007
.
Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia.
Respiration
74
:
159
169
.
22
Daniil
Z.
,
Kitsanta
P.
,
Kapotsis
G.
,
Mathioudaki
M.
,
Kollintza
A.
,
Karatza
M.
,
Milic-Emili
J.
,
Roussos
C.
,
Papiris
S. A.
.
2005
.
CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis.
Respir. Res.
6
:
81
.
23
Erickson
S. B.
,
Kurtz
S. B.
,
Donadio
J. V.
 Jr.
,
Holley
K. E.
,
Wilson
C. B.
,
Pineda
A. A.
.
1979
.
Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture’s syndrome.
Mayo Clin. Proc.
54
:
714
720
.
24
Sem
M.
,
Molberg
O.
,
Lund
M. B.
,
Gran
J. T.
.
2009
.
Rituximab treatment of the anti-synthetase syndrome: a retrospective case series.
Rheumatology
48
:
968
971
.
25
Martinu
T.
,
Howell
D. N.
,
Palmer
S. M.
.
2010
.
Acute cellular rejection and humoral sensitization in lung transplant recipients.
Semin. Respir. Crit. Care Med.
31
:
179
188
.
26
Borie
R.
,
Debray
M. P.
,
Laine
C.
,
Aubier
M.
,
Crestani
B.
.
2009
.
Rituximab therapy in autoimmune pulmonary alveolar proteinosis.
Eur. Respir. J.
33
:
1503
1506
.
27
Keir
G. J.
,
Maher
T. M.
,
Hansell
D. M.
,
Denton
C. P.
,
Ong
V. H.
,
Singh
S.
,
Wells
A. U.
,
Renzoni
E. A.
.
2012
.
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.
Eur. Respir. J.
40
:
641
648
.
28
Furie
R.
,
Petri
M.
,
Zamani
O.
,
Cervera
R.
,
Wallace
D. J.
,
Tegzová
D.
,
Sanchez-Guerrero
J.
,
Schwarting
A.
,
Merrill
J. T.
,
Chatham
W. W.
, et al
BLISS-76 Study Group
.
2011
.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Arthritis Rheum.
63
:
3918
3930
.
29
Cancro
M. P.
,
D’Cruz
D. P.
,
Khamashta
M. A.
.
2009
.
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.
J. Clin. Invest.
119
:
1066
1073
.
30
Feghali-Bostwick
C. A.
,
Gadgil
A. S.
,
Otterbein
L. E.
,
Pilewski
J. M.
,
Stoner
M. W.
,
Csizmadia
E.
,
Zhang
Y.
,
Sciurba
F. C.
,
Duncan
S. R.
.
2008
.
Autoantibodies in patients with chronic obstructive pulmonary disease.
Am. J. Respir. Crit. Care Med.
177
:
156
163
.
31
Bon
J.
,
Fuhrman
C. R.
,
Weissfeld
J. L.
,
Duncan
S. R.
,
Branch
R. A.
,
Chang
C. C.
,
Zhang
Y.
,
Leader
J. K.
,
Gur
D.
,
Greenspan
S. L.
,
Sciurba
F. C.
.
2011
.
Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort.
Am. J. Respir. Crit. Care Med.
183
:
885
890
.
32
Levesque
M. C.
,
Moody
M. A.
,
Hwang
K. K.
,
Marshall
D. J.
,
Whitesides
J. F.
,
Amos
J. D.
,
Gurley
T. C.
,
Allgood
S.
,
Haynes
B. B.
,
Vandergrift
N. A.
, et al
.
2009
.
Transmitted/Founder HIV-1 induces B cell polyclonal differentiation and apoptosis with massive gastrointestinal tract germinal center loss in the earliest stages of infection.
PLoS Med.
6
:
e1000107
.
33
Hogg
J. C.
,
Chu
F.
,
Utokaparch
S.
,
Woods
R.
,
Elliott
W. M.
,
Buzatu
L.
,
Cherniack
R. M.
,
Rogers
R. M.
,
Sciurba
F. C.
,
Coxson
H. O.
,
Paré
P. D.
.
2004
.
The nature of small-airway obstruction in chronic obstructive pulmonary disease.
N. Engl. J. Med.
350
:
2645
2653
.
34
Browning
J. L.
2006
.
B cells move to center stage: novel opportunities for autoimmune disease treatment.
Nat. Rev. Immunol.
5
:
564
575
.
35
Jacobi
A. M.
,
Reiter
K.
,
Mackay
M.
,
Aranow
C.
,
Hiepe
F.
,
Radbruch
A.
,
Hansen
A.
,
Burmester
G. R.
,
Diamond
B.
,
Lipsky
P. E.
,
Dörner
T.
.
2008
.
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95.
Arthritis Rheum.
58
:
1762
1773
.
36
Souto-Carneiro
M. M.
,
Mahadevan
V.
,
Takada
K.
,
Fritsch-Stork
R.
,
Nanki
T.
,
Brown
M.
,
Fleisher
T. A.
,
Wilson
M.
,
Goldbach-Mansky
R.
,
Lipsky
P. E.
.
2009
.
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.
Arthritis Res. Ther.
11
:
R84
.
37
Anolik
J. H.
,
Barnard
J.
,
Cappione
A.
,
Pugh-Bernard
A. E.
,
Felgar
R. E.
,
Looney
R. J.
,
Sanz
I.
.
2004
.
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
Arthritis Rheum.
50
:
3580
3590
.
38
Bossen
C.
,
Schneider
P.
.
2006
.
BAFF, APRIL and their receptors: structure, function and signaling.
Semin. Immunol.
18
:
263
275
.
39
Dillon
S. R.
,
Harder
B.
,
Lewis
K. B.
,
Moore
M. D.
,
Liu
H.
,
Bukowski
T. R.
,
Hamacher
N. B.
,
Lantry
M. M.
,
Maurer
M.
,
Krejsa
C. M.
, et al
.
2010
.
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Arthritis Res. Ther.
12
:
R48
.
40
Mayadas
T. N.
,
Tsokos
G. C.
,
Tsuboi
N.
.
2009
.
Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.
Circulation
120
:
2012
2024
.
41
Fu
S. M.
,
Deshmukh
U. S.
,
Gaskin
F.
.
2011
.
Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR.
J. Autoimmun.
37
:
104
112
.
42
Yokota
S.-I.
,
Chiba
S.
,
Furuyama
H.
,
Fujii
N.
.
2010
.
Cerebrospinal fluids containing anti-HSP70 autoantibodies from multiple sclerosis patients augment HSP70-induced proinflammatory cytokine production in monocytic cells.
J. Neuroimmunol.
218
:
129
133
.
43
Lu
M. C.
,
Lai
N. S.
,
Yu
H. C.
,
Huang
H. B.
,
Hsieh
S. C.
,
Yu
C. L.
.
2010
.
Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production.
Arthritis Rheum.
62
:
1213
1223
.
44
Jang
J. Y.
,
Jeong
J. G.
,
Jun
H. R.
,
Lee
S. C.
,
Kim
J. S.
,
Kim
Y. S.
,
Kwon
M. H.
.
2009
.
A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity.
Cell. Mol. Life Sci.
66
:
1985
1997
.
45
Richards
T. J.
,
Kaminski
N.
,
Baribaud
F.
,
Flavin
S.
,
Brodmerkel
C.
,
Horowitz
D.
,
Li
K.
,
Choi
J.
,
Vuga
L. J.
,
Lindell
K. O.
, et al
.
2012
.
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.
Am. J. Respir. Crit. Care Med.
185
:
67
76
.
46
Aloisi
F.
,
Pujol-Borrell
R.
.
2006
.
Lymphoid neogenesis in chronic inflammatory disease.
Nat. Rev. Immunol.
6
:
205
217
.
47
Perros
F.
,
Dorfmüller
P.
,
Montani
D.
,
Hammad
H.
,
Waelput
W.
,
Girerd
B.
,
Raymond
N.
,
Mercier
O.
,
Mussot
S.
,
Cohen-Kaminsky
S.
, et al
.
2012
.
Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension.
Am. J. Respir. Crit. Care Med.
185
:
311
321
.
48
Monaco
C.
,
Andreakos
E.
,
Kiriakidis
S.
,
Feldmann
M.
,
Paleolog
E.
.
2004
.
T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases.
Curr. Drug Targets Inflamm. Allergy
3
:
35
42
.
49
Wynn
T. A.
2004
.
Fibrotic disease and the TH1/TH2 paradigm.
Nat. Rev. Immunol.
4
:
583
594
.
50
Donahoe, M., N. Chien, J. S. Raval, K. F. Gibson, M. Saul, Y. Zhang, and S. R. Duncan. 2013. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. Presented at the Am Thorac Soc International Meeting, May 2013. Am. J. Resp. Crit. Care Med. 187: A5712. Available at: http://cms.psav.com/cPaper2013/ats2013/myitinerary. Accessed: June 4, 2013

The authors have no financial conflicts of interest.